AGL 38.54 Increased By ▲ 0.97 (2.58%)
AIRLINK 129.50 Decreased By ▼ -3.00 (-2.26%)
BOP 5.61 Decreased By ▼ -0.03 (-0.53%)
CNERGY 3.86 Increased By ▲ 0.09 (2.39%)
DCL 8.73 Decreased By ▼ -0.14 (-1.58%)
DFML 41.76 Increased By ▲ 0.76 (1.85%)
DGKC 88.30 Decreased By ▼ -1.86 (-2.06%)
FCCL 35.00 Decreased By ▼ -0.08 (-0.23%)
FFBL 67.35 Increased By ▲ 0.85 (1.28%)
FFL 10.61 Increased By ▲ 0.46 (4.53%)
HUBC 108.76 Increased By ▲ 2.36 (2.22%)
HUMNL 14.66 Increased By ▲ 1.26 (9.4%)
KEL 4.75 Decreased By ▼ -0.11 (-2.26%)
KOSM 6.95 Increased By ▲ 0.10 (1.46%)
MLCF 41.65 Decreased By ▼ -0.15 (-0.36%)
NBP 59.60 Increased By ▲ 1.02 (1.74%)
OGDC 183.00 Increased By ▲ 1.75 (0.97%)
PAEL 26.25 Increased By ▲ 0.55 (2.14%)
PIBTL 5.97 Increased By ▲ 0.14 (2.4%)
PPL 146.70 Decreased By ▼ -1.70 (-1.15%)
PRL 23.61 Increased By ▲ 0.39 (1.68%)
PTC 16.56 Increased By ▲ 1.32 (8.66%)
SEARL 68.30 Decreased By ▼ -0.49 (-0.71%)
TELE 7.23 Decreased By ▼ -0.01 (-0.14%)
TOMCL 35.95 Decreased By ▼ -0.05 (-0.14%)
TPLP 7.85 Increased By ▲ 0.45 (6.08%)
TREET 14.20 Decreased By ▼ -0.04 (-0.28%)
TRG 50.45 Decreased By ▼ -0.40 (-0.79%)
UNITY 26.75 Increased By ▲ 0.35 (1.33%)
WTL 1.21 No Change ▼ 0.00 (0%)
BR100 9,806 Increased By 37.8 (0.39%)
BR30 29,678 Increased By 278.1 (0.95%)
KSE100 92,304 Increased By 366.3 (0.4%)
KSE30 28,840 Increased By 96.6 (0.34%)

KARACHI: Lucky Core Industries Limited (LCI) is pleased to announce that on May 17, the company executed Asset Purchase Agreements with Pfizer Pakistan Limited and Pfizer Inc., a leading global pharmaceutical group, for the acquisition of certain assets.

The assets being acquired by LCI through this transaction include a manufacturing facility owned by Pfizer Pakistan Limited located in Karachi, along with a portfolio of well-established pharmaceutical brands, namely Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D and Mycitracin, as well as trademarks associated with the said pharmaceutical products (either through an outright assignment of trademarks or a perpetual license to use the relevant trademarks). These leading brands are primary care products in the therapeutic areas including, pain, skin infections, and vitamin deficiencies, and have strong potential for growth in the market.

Chief Executive LCI, Asif Jooma, commented: “This acquisition marks a significant milestone in our journey towards accelerating growth of our Pharmaceuticals business. By adding these established brands to our portfolio, we will further enrich the lives of those around us by continuing to deliver quality medicines and healthcare products, while expanding our manufacturing base, diversifying our product offerings, and implementing synergies to strengthen our position in the marketplace.”

Copyright Business Recorder, 2024

Comments

Comments are closed.